BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012;132:2166-2170. [PMID: 22534879 DOI: 10.1038/jid.2012.130] [Cited by in Crossref: 118] [Cited by in F6Publishing: 80] [Article Influence: 13.1] [Reference Citation Analysis]
Number Citing Articles
1 Franklin S, Sabharwal S, Hettiaratchy S, Reilly P. When infection isn't infection. Ann R Coll Surg Engl 2020;102:e183-4. [PMID: 32347737 DOI: 10.1308/rcsann.2020.0091] [Reference Citation Analysis]
2 O'Connor C, Gallagher C, Hollywood A, Paul L, O'Connell M. Anakinra for recalcitrant pyoderma gangrenosum. Clin Exp Dermatol 2021. [PMID: 34137070 DOI: 10.1111/ced.14809] [Reference Citation Analysis]
3 Plumptre I, Knabel D, Tomecki K. Pyoderma Gangrenosum: A Review for the Gastroenterologist. Inflamm Bowel Dis 2018;24:2510-7. [PMID: 29788368 DOI: 10.1093/ibd/izy174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
4 Janowska A, Oranges T, Fissi A, Davini G, Romanelli M, Dini V. PG-TIME: A practical approach to the clinical management of pyoderma gangrenosum. Dermatol Ther 2020;33:e13412. [PMID: 32291879 DOI: 10.1111/dth.13412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Maglie R, Genovese G, Solimani F, Guglielmo A, Pileri A, Portelli F, Hertl M, Marzano AV, Antiga E. Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review. Am J Clin Dermatol 2020;21:833-54. [PMID: 32813229 DOI: 10.1007/s40257-020-00553-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
6 Bingoel AS, Krezdorn N, Kaltenborn A, Dastagir K, Jokuszies A, Mett TR, Vogt PM. The surgical approach to Pyoderma gangrenosum: A retrospective monocenter study. Wound Repair Regen 2021;29:478-85. [PMID: 33835625 DOI: 10.1111/wrr.12918] [Reference Citation Analysis]
7 Haag CK, Nutan F, Cyrus JW, Satpathy J, Shinkai K, Ortega Loayza AG. Pyoderma gangrenosum misdiagnosis resulting in amputation: A review. J Trauma Acute Care Surg 2019;86:307-13. [DOI: 10.1097/ta.0000000000002096] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Jockenhöfer F, Klode J, Kröger K, Roesch A, Al Ghazal P, Dissemond J. Patients with pyoderma gangrenosum - analyses of the German DRG data from 2012. Int Wound J 2016;13:951-6. [PMID: 26250591 DOI: 10.1111/iwj.12463] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kridin K, Laufer Britva R, Tzur Bitan D, Damiani G, Cohen AD. Is pyoderma gangrenosum associated with solid malignancies? Insights from a population-based cohort study. Australas J Dermatol 2021;62:336-41. [PMID: 34076886 DOI: 10.1111/ajd.13631] [Reference Citation Analysis]
10 Pearson WA, Prentice DA, Sinclair DL, Lim LY, Carville KJ. A novel topical therapy for resistant and early peristomal pyoderma gangrenosum. Int Wound J 2019;16:1136-43. [PMID: 31298491 DOI: 10.1111/iwj.13164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Nieto D, Sendagorta E, Rueda JM, Herranz P. Successful treatment with ustekinumab and vacuum-assisted closure therapy in recalcitrant myelodysplastic syndrome-associated pyoderma gangrenosum: case report and literature review. Clin Exp Dermatol 2019;44:116-9. [DOI: 10.1111/ced.13679] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
12 Mason JM, Thomas KS, Ormerod AD, Craig FE, Mitchell E, Norrie J, Williams HC; U.K. Dermatology Clinical Trials Network's STOP GAP team. Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial. Br J Dermatol 2017;177:1527-36. [PMID: 28391619 DOI: 10.1111/bjd.15561] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
13 Teagle A, Hargest R. Management of pyoderma gangrenosum. J R Soc Med 2014;107:228-36. [PMID: 24912791 DOI: 10.1177/0141076814534407] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
14 George C, Deroide F, Rustin M. Pyoderma gangrenosum - a guide to diagnosis and management. Clin Med (Lond). 2019;19:224-228. [PMID: 31092515 DOI: 10.7861/clinmedicine.19-3-224] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 29.0] [Reference Citation Analysis]
15 Garcovich S, De Simone C, Berti E, Marzano AV. Drug management of neutrophilic dermatoses. Expert Rev Clin Pharmacol 2017;10:1119-28. [PMID: 28715916 DOI: 10.1080/17512433.2017.1356719] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
16 Tominaga K, Kamimura K, Sato H, Ko M, Kawata Y, Mizusawa T, Yokoyama J, Terai S. Cytapheresis for pyoderma gangrenosum associated with inflammatory bowel disease: A review of current status. World J Clin Cases 2020;8:2092-101. [PMID: 32548138 DOI: 10.12998/wjcc.v8.i11.2092] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Thomas KS, Batchelor JM, Bath-hextall F, Chalmers JR, Clarke T, Crowe S, Delamere FM, Eleftheriadou V, Evans N, Firkins L, Greenlaw N, Lansbury L, Lawton S, Layfield C, Leonardi-bee J, Mason J, Mitchell E, Nankervis H, Norrie J, Nunn A, Ormerod AD, Patel R, Perkins W, Ravenscroft JC, Schmitt J, Simpson E, Whitton ME, Williams HC. A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease. Programme Grants Appl Res 2016;4:1-488. [DOI: 10.3310/pgfar04180] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Feldman SR, Lacy FA, Huang WW. The safety of treatments used in pyoderma gangrenosum. Expert Opinion on Drug Safety 2018;17:55-61. [DOI: 10.1080/14740338.2018.1396316] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
19 Adışen E, Erduran F, Gürer MA. Pyoderma Gangrenosum: A Report of 27 Patients. Int J Low Extrem Wounds 2016;15:148-54. [PMID: 27009790 DOI: 10.1177/1534734616639172] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
20 Ohashi T, Miura T, Yamamoto T. Auricular pyoderma gangrenosum with penetration in a patient with rheumatoid arthritis. Int J Rheum Dis. 2014;Jun 10; Epub ahead of print. [PMID: 24916772 DOI: 10.1111/1756-185x.12411] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Montagnon CM, Fracica EA, Patel AA, Camilleri MJ, Murad MH, Dingli D, Wetter DA, Tolkachjov SN. Pyoderma gangrenosum in hematologic malignancies: A systematic review. J Am Acad Dermatol 2020;82:1346-59. [PMID: 31560977 DOI: 10.1016/j.jaad.2019.09.032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
22 Ghumra W, Gold A, Azurdia RM. Pyoderma gangrenosum following an unplanned caesarean section: a patient revisited. BMJ Case Rep 2021;14:e238702. [PMID: 33619133 DOI: 10.1136/bcr-2020-238702] [Reference Citation Analysis]
23 Pukar C, Sudha A, Punam P. Simultaneous occurrence of Pyoderma Gangrenosum and Palmoplantar Pustular Psoriasis: Is it an association or coincidental findings? Clin Case Rep 2021;9:410-5. [PMID: 33489191 DOI: 10.1002/ccr3.3544] [Reference Citation Analysis]
24 Khan F, Radovanovic A, Gojobori T, Kaur M. IBDDB: a manually curated and text-mining-enhanced database of genes involved in inflammatory bowel disease. Database (Oxford) 2021;2021:baab022. [PMID: 33929018 DOI: 10.1093/database/baab022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kaffenberger BH, Hinton A, Krishna SG. The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. J Am Acad Dermatol 2018;79:659-663.e2. [PMID: 29438762 DOI: 10.1016/j.jaad.2018.02.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
26 Wu XR, Shen B. Diagnosis and management of parastomal pyoderma gangrenosum. Gastroenterol Rep (Oxf) 2013;1:1-8. [PMID: 24759661 DOI: 10.1093/gastro/got013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
27 Lu JD, Milakovic M, Ortega-Loayza AG, Marzano AV, Alavi A. Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1. Expert Opin Investig Drugs 2020;29:1179-85. [PMID: 32880206 DOI: 10.1080/13543784.2020.1819981] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Wollina U. Pyoderma gangrenosum—a systemic disease? Clinics in Dermatology 2015;33:527-30. [DOI: 10.1016/j.clindermatol.2015.05.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
29 Monari P, Moro R, Motolese A, Misciali C, Baraldi C, Fanti PA, Caccavale S, Puviani M, Olezzi D, Zampieri P, Trevisan G, Nan K, Fiorentini C, Pellacani G, Gualdi G. Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre study. Int Wound J 2018;15:875-9. [PMID: 29877043 DOI: 10.1111/iwj.12939] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
30 Gameiro A, Pereira N, Cardoso JC, Gonçalo M. Pyoderma gangrenosum: challenges and solutions. Clin Cosmet Investig Dermatol 2015;8:285-93. [PMID: 26060412 DOI: 10.2147/CCID.S61202] [Cited by in Crossref: 49] [Cited by in F6Publishing: 9] [Article Influence: 8.2] [Reference Citation Analysis]
31 Saleh MFM, Saunthararajah Y. Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen. Clin Case Rep 2017;5:2025-7. [PMID: 29225849 DOI: 10.1002/ccr3.1221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
32 Song H, Lahood N, Mostaghimi A. Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series. Br J Dermatol 2018;178:363-8. [PMID: 28742926 DOI: 10.1111/bjd.15850] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 7.3] [Reference Citation Analysis]
33 Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol 2018;14:225-33. [PMID: 29406827 DOI: 10.1080/1744666X.2018.1438269] [Cited by in Crossref: 41] [Cited by in F6Publishing: 9] [Article Influence: 13.7] [Reference Citation Analysis]
34 Tay DZ, Tan KW, Tay YK. Pyoderma gangrenosum: a commonly overlooked ulcerative condition. J Family Med Prim Care 2014;3:374-8. [PMID: 25657946 DOI: 10.4103/2249-4863.148113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
35 Marotto D, Atzeni F, Ardizzone S, Monteleone G, Giorgi V, Sarzi-Puttini P. Extra-intestinal manifestations of inflammatory bowel diseases. Pharmacol Res 2020;161:105206. [PMID: 32998068 DOI: 10.1016/j.phrs.2020.105206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
36 Fletcher J, Alhusayen R, Alavi A. Recent advances in managing and understanding pyoderma gangrenosum. F1000Res 2019;8:F1000 Faculty Rev-2092. [PMID: 31885859 DOI: 10.12688/f1000research.19909.1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
37 Defilippis E, Feldman S, Huang W. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. Br J Dermatol 2015;172:1487-97. [DOI: 10.1111/bjd.13493] [Cited by in Crossref: 57] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
38 Gastman B, Hashem AM, Djohan R, Bernard S, Hendrickson M, Schwarz G, Gharb BB, Rampazzo A, Fernandez A, Zins J, Hoffman GS, Doumit G, Siemionow M, Papay F. Malignant Pyoderma Associated with Granulomatosis with Polyangiitis (Wegener Granulomatosis) as a Unique Indication for Facial Vascularized Composite Allotransplantation: Part I. Plast Reconstr Surg 2016;137:1007e-15e. [PMID: 27219252 DOI: 10.1097/PRS.0000000000002162] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 de Souza EF, da Silva GA, Dos Santos GR, Motta HL, Cardoso PA, de Azevedo MC, Pires KL, Motta RN, Eyer Silva Wde A, Ferry FR, Pinto JF. Pyoderma Gangrenosum Simulating Necrotizing Fasciitis. Case Rep Med 2015;2015:504970. [PMID: 26783395 DOI: 10.1155/2015/504970] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
40 Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, Mason JM, Walton S, Johnston GA, Williams HC; UK Dermatology Clinical Trials Network’s STOP GAP Team. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 2015;350:h2958. [PMID: 26071094 DOI: 10.1136/bmj.h2958] [Cited by in Crossref: 121] [Cited by in F6Publishing: 71] [Article Influence: 20.2] [Reference Citation Analysis]
41 Yamamoto T. Pyoderma gangrenosum: An important dermatologic condition occasionally associated with rheumatic diseases. WJR 2015;5:101. [DOI: 10.5499/wjr.v5.i2.101] [Cited by in CrossRef: 3] [Article Influence: 0.5] [Reference Citation Analysis]
42 Maverakis E, Marzano AV, Le ST, Callen JP, Brüggen M, Guenova E, Dissemond J, Shinkai K, Langan SM. Pyoderma gangrenosum. Nat Rev Dis Primers 2020;6. [DOI: 10.1038/s41572-020-0213-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
43 Tolkachjov SN, Fahy AS, Cerci FB, Wetter DA, Cha SS, Camilleri MJ. Postoperative Pyoderma Gangrenosum: A Clinical Review of Published Cases. Mayo Clin Proc 2016;91:1267-79. [PMID: 27489052 DOI: 10.1016/j.mayocp.2016.05.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 5.6] [Reference Citation Analysis]
44 Reid AB, Stanley P, Grinsell D, Daffy JR. Severe, Steroid-responsive, Myositis Mimicking Necrotizing Fasciitis following Orthopedic Surgery: A Pyoderma Variant with Myonecrosis. Plast Reconstr Surg Glob Open 2014;2:e175. [PMID: 25289368 DOI: 10.1097/GOX.0000000000000124] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
45 Thomas KS, Ormerod AD, Craig FE, Greenlaw N, Norrie J, Mitchell E, Mason JM, Johnston GA, Wahie S, Williams HC; UK Dermatology Clinical Trials Network's STOP GAP Team. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study. J Am Acad Dermatol 2016;75:940-9. [PMID: 27502313 DOI: 10.1016/j.jaad.2016.06.016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 6.2] [Reference Citation Analysis]
46 Pichler M, Thuile T, Gatscher B, Tappeiner L, Deluca J, Larcher L, Holzer M, Nguyen V, Exler G, Schmuth M, Klein G, Eisendle K. Systematic review of surgical treatment of pyoderma gangrenosum with negative pressure wound therapy or skin grafting. J Eur Acad Dermatol Venereol 2017;31:e61-7. [DOI: 10.1111/jdv.13727] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
47 Wollina U, Tchernev G. Pyoderma gangrenosum: pathogenetic oriented treatment approaches. Wien Med Wochenschr 2014;164:263-73. [DOI: 10.1007/s10354-014-0285-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
48 Kridin K, Solomon A, Britva RL, Bitan DT, Cohen AD. Chronic renal comorbidities in pyoderma gangrenosum: a retrospective cohort study. Immunol Res 2021;69:249-54. [PMID: 33890227 DOI: 10.1007/s12026-021-09187-3] [Reference Citation Analysis]
49 Vavricka SR, Galván JA, Dawson H, Soltermann A, Biedermann L, Scharl M, Schoepfer AM, Rogler G, Prinz Vavricka MB, Terracciano L, Navarini A, Zlobec I, Lugli A, Greuter T. Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2018;12:347-54. [DOI: 10.1093/ecco-jcc/jjx158] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
50 Kolios A, Maul J, Meier B, Kerl K, Traidl‐hoffmann C, Hertl M, Zillikens D, Röcken M, Ring J, Facchiano A, Mondino C, Yawalkar N, Contassot E, Navarini A, French L. Canakinumab in adults with steroid‐refractory pyoderma gangrenosum. Br J Dermatol 2015;173:1216-23. [DOI: 10.1111/bjd.14037] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
51 Kawai M, Kawanami C, Fukuda A, Seno H. Pyoderma gangrenosum with primary sclerosing cholangitis-associated colitis successfully treated with concomitant granulocyte and monocyte adsorption apheresis with corticosteroids. Clin J Gastroenterol 2021. [PMID: 34101129 DOI: 10.1007/s12328-021-01460-0] [Reference Citation Analysis]
52 Soleimani T, Sasor SE, Spera L, Eppley BE, Socas J, Chu MW, Tholpady SS. Pediatric pyoderma gangrenosum: is it just big wounds on little adults? Journal of Surgical Research 2016;206:113-7. [DOI: 10.1016/j.jss.2016.06.045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
53 Marzano AV, Borghi A, Wallach D, Cugno M. A Comprehensive Review of Neutrophilic Diseases. Clinic Rev Allerg Immunol 2018;54:114-30. [DOI: 10.1007/s12016-017-8621-8] [Cited by in Crossref: 63] [Cited by in F6Publishing: 36] [Article Influence: 15.8] [Reference Citation Analysis]
54 Rodríguez-Zúñiga MJM, Heath MS, Gontijo JRV, Ortega-Loayza AG. Pyoderma gangrenosum: a review with special emphasis on Latin America literature. An Bras Dermatol 2019;94:729-43. [PMID: 31789268 DOI: 10.1016/j.abd.2019.06.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
55 Soto Vilches F, Vera-kellet C. Pioderma gangrenoso: terapias clásicas y emergentes. Medicina Clínica 2017;149:256-60. [DOI: 10.1016/j.medcli.2017.04.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
56 Vallini V, Andreini R, Bonadio A. Pyoderma Gangrenosum: A Current Problem as Much as an Unknown One. The International Journal of Lower Extremity Wounds 2017;16:191-201. [DOI: 10.1177/1534734617710980] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
57 Nahi H, Afram G, Brauner H, Talme T, Kuzmina N. Pyoderma gangrenosum with plasma cell dyscrasia should be subject for anti-myeloma treatment. Int J Dermatol 2021;60:e271-3. [PMID: 33751551 DOI: 10.1111/ijd.15504] [Reference Citation Analysis]
58 Al Ghazal P, Herberger K, Schaller J, Strölin A, Hoff NP, Goerge T, Roth H, Rabe E, Karrer S, Renner R. Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis. 2013;8:136. [PMID: 24010984 DOI: 10.1186/1750-1172-8-136] [Cited by in Crossref: 76] [Cited by in F6Publishing: 45] [Article Influence: 9.5] [Reference Citation Analysis]
59 Lebrun D, Robbins A, Hentzien M, Toquet S, Plee J, Durlach A, Bouaziz JD, Bani-Sadr F, Servettaz A. Two case reports of pyoderma gangrenosum and systemic lupus erythematosus: A rare but nonfortuitous association? Medicine (Baltimore) 2018;97:e11933. [PMID: 30142811 DOI: 10.1097/MD.0000000000011933] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Partridge ACR, Bai JW, Rosen CF, Walsh SR, Gulliver WP, Fleming P. Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials. Br J Dermatol 2018;179:290-5. [PMID: 29478243 DOI: 10.1111/bjd.16485] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
61 Herberger K. [Pyoderma gangrenosum]. Hautarzt 2016;67:753-63. [PMID: 27492434 DOI: 10.1007/s00105-016-3847-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
62 Vacas AS, Torre AC, Bollea-garlatti ML, Warley F, Galimberti RL. Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients. Int J Dermatol 2017;56:386-91. [DOI: 10.1111/ijd.13591] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
63 Sasor SE, Soleimani T, Chu MW, Cook JA, Nicksic PJ, Tholpady SS. Pyoderma gangrenosum demographics, treatments, and outcomes: an analysis of 2,273 cases. J Wound Care 2018;27:S4-8. [PMID: 29334018 DOI: 10.12968/jowc.2018.27.Sup1.S4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
64 Marzano AV, Ceccherini I, Gattorno M, Fanoni D, Caroli F, Rusmini M, Grossi A, De Simone C, Borghi OM, Meroni PL, Crosti C, Cugno M. Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine (Baltimore) 2014;93:e187. [PMID: 25501066 DOI: 10.1097/MD.0000000000000187] [Cited by in Crossref: 75] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
65 Gade M, Studstrup F, Andersen AK, Hilberg O, Fogh C, Bendstrup E. Pulmonary manifestations of pyoderma gangrenosum: 2 cases and a review of the literature. Respir Med 2015;109:443-50. [PMID: 25622759 DOI: 10.1016/j.rmed.2014.12.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
66 Jockenhöfer F, Herberger K, Schaller J, Hohaus KC, Stoffels-Weindorf M, Ghazal PA, Augustin M, Dissemond J. Tricenter analysis of cofactors and comorbidity in patients with pyoderma gangrenosum. J Dtsch Dermatol Ges 2016;14:1023-30. [PMID: 27767288 DOI: 10.1111/ddg.12791] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
67 Kridin K, Cohen AD, Amber KT. Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis. Am J Clin Dermatol 2018;19:479-87. [PMID: 29721816 DOI: 10.1007/s40257-018-0356-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 9.7] [Reference Citation Analysis]
68 Sawka E, Zhou A, Latour E, Friedman M, Ortega-Loayza AG. Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review. Clin Rheumatol 2021. [PMID: 34002351 DOI: 10.1007/s10067-021-05768-7] [Reference Citation Analysis]
69 Deregnaucourt D, Buche S, Coopman S, Basraoui D, Turck D, Delaporte E. Pyoderma gangrenosum avec localisations pulmonaires traité par infliximab. Annales de Dermatologie et de Vénéréologie 2013;140:363-6. [DOI: 10.1016/j.annder.2013.01.428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
70 Haag CK, Ortega-loayza AG, Latour E, Keller JJ, Fett NM. Clinical factors influencing the response to intravenous immunoglobulin treatment in cases of treatment-resistant pyoderma gangrenosum. Journal of Dermatological Treatment 2020;31:723-6. [DOI: 10.1080/09546634.2019.1606888] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
71 Cosgarea R, Senilă SC, Badea R, Ungureanu L. Pyoderma gangrenosum with spleen involvement. Review of the literature and case report. J Dermatol Case Rep 2016;10:26-31. [PMID: 27900062 DOI: 10.3315/jdcr.2016.1230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Wallach D, Vignon-Pennamen MD. Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses. Br J Dermatol 2018;178:595-602. [PMID: 26202386 DOI: 10.1111/bjd.13955] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
73 Eisendle K, Thuile T, Deluca J, Pichler M. Surgical Treatment of Pyoderma Gangrenosum with Negative Pressure Wound Therapy and Skin Grafting, Including Xenografts: Personal Experience and Comprehensive Review on 161 Cases. Adv Wound Care (New Rochelle) 2020;9:405-25. [PMID: 32320362 DOI: 10.1089/wound.2020.1160] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
74 Isoherranen K, O'brien JJ, Barker J, Dissemond J, Hafner J, Jemec GBE, Kamarachev J, Läuchli S, Montero EC, Nobbe S, Sunderkötter C, Velasco ML. Atypical wounds. Best clinical practice and challenges. J Wound Care 2019;28:S1-S92. [DOI: 10.12968/jowc.2019.28.sup6.s1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
75 Marzano AV, Damiani G, Ceccherini I, Berti E, Gattorno M, Cugno M. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol. 2017;176:1588-1598. [PMID: 27943240 DOI: 10.1111/bjd.15226] [Cited by in Crossref: 101] [Cited by in F6Publishing: 70] [Article Influence: 25.3] [Reference Citation Analysis]
76 Fousekis FS, Saridi M, Albani E, Daniel F, Katsanos KH, Kastanioudakis IG, Christodoulou DK. Ear Involvement in Inflammatory Bowel Disease: A Review of the Literature. J Clin Med Res 2018;10:609-14. [PMID: 29977417 DOI: 10.14740/jocmr3465w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
77 Gupta AS, Ortega-loayza AG. Pyoderma gangrenosum: a too often overlooked facultative paraneoplastic disease. Ann Hematol 2019;98:2247-8. [DOI: 10.1007/s00277-019-03732-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
78 Cugno M, Gualtierotti R, Meroni PL, Marzano AV. Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review. Clinic Rev Allerg Immunol 2018;54:269-81. [DOI: 10.1007/s12016-017-8629-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
79 Card TR, Langan SM, Chu TPC. Extra-Gastrointestinal Manifestations of Inflammatory Bowel Disease May Be Less Common Than Previously Reported. Dig Dis Sci 2016;61:2619-26. [DOI: 10.1007/s10620-016-4195-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
80 Gupta AS, Greiling TM, Ortega-Loayza AG. A systematic review of pyoderma gangrenosum with pulmonary involvement: clinical presentation, diagnosis and management. J Eur Acad Dermatol Venereol 2018;32:e295-7. [PMID: 29377399 DOI: 10.1111/jdv.14828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]